Matchpoint Therapeutics is preparing to take its oral T cell modulator through proof-of-concept clinical testing in ...

The new study is the first readout for a drug added by the Forte takeover, which closed in August, and will relieve some of ...

As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira ...

Pfizer acquired Tukysa as part of its $43 billion takeover of Seagen in 2023, three years after the drug first reached the US ...

Raising funding, assembling the initial team, building lab operations from the ground up, generating proof-of-concept ...

The Nobel Prize in Chemistry 2026 has been awarded to two scientists - Henri B Kagan and Kensō Soai – for discoveries on ...

US pharma trade organisation PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation (MFN) ...

Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in ...

Just months after launching an open-source 'virtual biology' platform, non-profit research organisation Biohub has raised ...

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include ​a second indication, symptomatic ...

MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...

A survey of senior figures in European biopharma companies has found that dealmaking and M&A are expected to increase, with ...